Skip to main content
All lobbying filings

TRAVERE THERAPEUTICS

TRAVERE THERAPEUTICS filed a Q1 report for TRAVERE THERAPEUTICS on April 16, 2025.

Lobbying for TRAVERE THERAPEUTICS · Biopharmaceuticals

All filings by TRAVERE THERAPEUTICS · Everything TRAVERE THERAPEUTICS has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 16, 2025
Expenses
$160,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act

HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act)

HR 1262, S 932 Give Kids a Chance Act to renew PRV program

Regulations regarding transparency, reimbursement and care, particularly regarding rare disease.

S.1040, to prohibit product hopping and for other purposes

H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%

 Bills named in this filing 5
  • H.R. 1518
    New Era of Preventing End-Stage Kidney Disease Act
  • H.R. 946
    ORPHAN Cures Act
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
  • S. 1040
    A bill to amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Veterans Healt…
  • H.R. 1414
    Cameron’s Law

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem